Electrophysiological Study of the Functioning of Magnocellular Visual Pathway in Regular Cannabis Users

NCT02864680 | Completed

• 1 other identifier: 2013-A00097-38
• Study Type: interventional
• Target: 163
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the impact of regular use of cannabis on the spatial sensitivity of magnocellular system (visual event-related potential, visual ERP). Secondary purposes of this study are to evaluate the impact of regular use of cannabis on the temporal sensitivity of magnocellular system (visual event-related potential), on the dynamics of cortical visual processing during face perception test (visual event-related potential) and on functioning of retinal photopic and scotopic systems (electroretinogram). The ancillary study is a genetic analysis of a group of candidate genes that aims to identify biomarkers for changes in visual processing. This will allow to distinguish among more homogeneous and specific groups in future studies on larger cannabis user population. This ancillary study concerns all participants subject to their informed consent (facultative study).

Conditions

Cannabis Use

Keywords

cannabis; magnocellular pathway

Outcome Measures

Primary Outcomes (2)

• Amplitude of P100 wave in contrast sensibility test

  up to 1 month

• Culmination time of the P100 wave in contrast sensibility test

  up to 1 month

Secondary Outcomes (10)

• Amplitude of P100 wave in visual simultaneity test

  up to 1 month

• Culmination time of P100 wave in visual simultaneity test

  up to 1 month

• Amplitude of P100 wave in face perception test

  up to 1 month

• Amplitude of N170 wave in face perception test

  up to 1 month

• Culmination time of P100 wave in face perception test

  up to 1 month

Other Outcomes (1)

• Relationship between variants of candidate genes for alterations of visual treatment and amplitude of P100 wave in contrast sensibility test

  up to 3 years

Study Arms (4)

Cannabis users

OTHER

Other: Electroretinography; Other: Contrast sensitivity test during Electroencephalography; Other: Visual simultaneity test during Electroencephalography; Other: Face perception test during Electroencephalography; Other: CAST (cannabis abuse screening test); Other: Delayed Matching to Sample (DMS) test; Other: Spatial Working Memory (SWM) test; Other: Rapid Visual Information Processing (RVP) test; Other: Test for attentional performance (TAP) / Divided Attention; Other: Collection of saliva sample

Healthy volunteers, not cannabis/tobacco users

OTHER

Other: Electroretinography; Other: Contrast sensitivity test during Electroencephalography; Other: Visual simultaneity test during Electroencephalography; Other: Face perception test during Electroencephalography; Other: Delayed Matching to Sample (DMS) test; Other: Spatial Working Memory (SWM) test; Other: Rapid Visual Information Processing (RVP) test; Other: Test for attentional performance (TAP) / Divided Attention; Other: Collection of saliva sample

Healthy volunteers, tobacco users

OTHER

Other: Electroretinography; Other: Contrast sensitivity test during Electroencephalography; Other: Visual simultaneity test during Electroencephalography; Other: Face perception test during Electroencephalography; Other: Delayed Matching to Sample (DMS) test; Other: Spatial Working Memory (SWM) test; Other: Rapid Visual Information Processing (RVP) test; Other: Test for attentional performance (TAP) / Divided Attention; Other: Collection of saliva sample

Schizophrenia patients

OTHER

Other: Electroretinography; Other: Contrast sensitivity test during Electroencephalography; Other: Visual simultaneity test during Electroencephalography; Other: Face perception test during Electroencephalography; Other: CAST (cannabis abuse screening test); Other: PANSS (Positive And Negative Symptoms Scale) test; Other: Delayed Matching to Sample (DMS) test; Other: Spatial Working Memory (SWM) test; Other: Rapid Visual Information Processing (RVP) test; Other: Test for attentional performance (TAP) / Divided Attention; Other: Collection of saliva sample

Interventions

Electroretinography OTHER

Cannabis users; Healthy volunteers, not cannabis/tobacco users; Healthy volunteers, tobacco users; Schizophrenia patients

Contrast sensitivity test during Electroencephalography OTHER

Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.

Cannabis users; Healthy volunteers, not cannabis/tobacco users; Healthy volunteers, tobacco users; Schizophrenia patients

Visual simultaneity test during Electroencephalography OTHER

Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.

Cannabis users; Healthy volunteers, not cannabis/tobacco users; Healthy volunteers, tobacco users; Schizophrenia patients

Face perception test during Electroencephalography OTHER

Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.

Cannabis users; Healthy volunteers, not cannabis/tobacco users; Healthy volunteers, tobacco users; Schizophrenia patients

CAST (cannabis abuse screening test) OTHER

Cannabis users; Schizophrenia patients

PANSS (Positive And Negative Symptoms Scale) test OTHER

Schizophrenia patients

Delayed Matching to Sample (DMS) test OTHER

Cannabis users; Healthy volunteers, not cannabis/tobacco users; Healthy volunteers, tobacco users; Schizophrenia patients

Spatial Working Memory (SWM) test OTHER

Cannabis users; Healthy volunteers, not cannabis/tobacco users; Healthy volunteers, tobacco users; Schizophrenia patients

Rapid Visual Information Processing (RVP) test OTHER

Cannabis users; Healthy volunteers, not cannabis/tobacco users; Healthy volunteers, tobacco users; Schizophrenia patients

Test for attentional performance (TAP) / Divided Attention OTHER

Cannabis users; Healthy volunteers, not cannabis/tobacco users; Healthy volunteers, tobacco users; Schizophrenia patients

Collection of saliva sample OTHER

In case of specific consent of participant to ancillary study, for ancillary study

Cannabis users; Healthy volunteers, not cannabis/tobacco users; Healthy volunteers, tobacco users; Schizophrenia patients

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Affiliation to social security plan
• Normal visual acuity or adjusted to normal and normal dilated fundus examination
• Signature of informed consent
• Cannabis user group: More than 7 cannabis uses per week during the previous month
• Cannabis user group: Positive urinary analysis for presence of cannabis
• Healthy, non user control group: Absence of cannabis and tobacco use during last 12 months
• Healthy, non user control group: Negative urinary analysis for presence of cannabis
• Healthy, non user control group: Age and sex matching with cannabis user group
• Healthy, tobacco user control group: Tobacco use from at least 12 months
• Healthy, tobacco user control group: Low to very strong addiction to tobacco (Fagerström test)
• Healthy, tobacco user control group: Absence of cannabis use from more than 12 months
• Healthy, tobacco user control group: Negative urinary analysis for presence of cannabis
• Healthy, tobacco user control group:Age and sex matching with cannabis user group
• Schizophrenia patient control group: Schizophrenia according to DMS IV criteria (MINI test)
• Schizophrenia patient control group: Absence of cannabis use from more than one month (regardless of tobacco use)

You may not qualify if:

• Acute psychiatric pathology (axis I of DSM IV, measured by MINI) except anxiety disorder (except schizophrenia group)
• Deficiency of the subject making difficult or impossible his/her participation to the study or the comprehension of the information
• Dyslexia
• Addiction to alcohol according to AUDIT scale
• Abuse or addiction to other substances according to DSM IV criteria
• Acute retinal disorder
• Chronic glaucoma
• Ophthalmic pathology affecting visual acuity
• Current ocular infection
• Persons under guardianship, curatorship or judicial protection
• Pregnant or breast-feeding women
• Persons with life-and-death emergency
• Absence of social security plan
• Results of preliminary medical examinations incompatible with the study
• Simultaneous participation to another therapeutic interventional study

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

Study Sites (1)

Maison des Addictions - CHU de Nancy, Hôpital St Julien

Nancy, France

Location

Related Publications (3)

• Remy I, Bernardin F, Ligier F, Krieg J, Maillard L, Schwan R, Schwitzer T, Laprevote V. Association between retinal and cortical visual electrophysiological impairments in schizophrenia. J Psychiatry Neurosci. 2023 May 19;48(3):E171-E178. doi: 10.1503/jpn.220224. Print 2023 May-Jun.

  PMID: 37208126 DERIVED

• Bernardin F, Schwitzer T, Schwan R, Angioi-Duprez K, Ligier F, Bourion-Bedes S, Jansen C, Giersch A, Laprevote V. Altered central vision and amacrine cells dysfunction as marker of hypodopaminergic activity in treated patients with schizophrenia. Schizophr Res. 2022 Jan;239:134-141. doi: 10.1016/j.schres.2021.11.049. Epub 2021 Dec 7.

  PMID: 34891077 DERIVED

• Remy I, Schwitzer T, Albuisson E, Schwan R, Krieg J, Bernardin F, Ligier F, Lalanne L, Maillard L, Laprevote V. Impaired P100 among regular cannabis users in response to magnocellular biased visual stimuli. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Mar 8;113:110437. doi: 10.1016/j.pnpbp.2021.110437. Epub 2021 Sep 11.

  PMID: 34520807 DERIVED

MeSH Terms

Conditions

Marijuana Abuse

Interventions

Gene Expression; Succimer

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Genetic Phenomena; Succinates; Dicarboxylic Acids; Acids, Acyclic; Carboxylic Acids; Organic Chemicals; Sulfhydryl Compounds; Sulfur Compounds

Study Officials

• Vincent LAPREVOTE

  Maison des Addictions - CHU de Nancy, France

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 3, 2016
• First Posted: August 12, 2016
• Study Start: February 1, 2014
• Primary Completion: June 1, 2019
• Study Completion: June 1, 2019
• Last Updated: April 29, 2021

Record last verified: 2019-06

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)